Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress
TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 23,555,648 | $129,556,064 | 1.33% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 21,700,000 | $119,350,000 | 1.17% | |
| 3. | Vestal Point Capital Ryan Wilder | 13,750,000 | $75,625,000 | +150% | 2.57% |
| 4. | Siren L.L.C. Raymond Debbane | 10,129,913 | $55,714,522 | -9% | 1.66% |
| 5. | Octagon Capital Advisors Ting Jia | 8,859,911 | $48,729,511 | -3% | 5.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 750,000 | $2,062,500.00 | 2,841,704 | 2025-05-30 | Filing | |
| $2.25 | 1,333,333 | $2,999,999.25 | 1,333,333 | 2024-06-27 | Filing | |
| $1.63 | 100,000 | $163,000.00 | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | $14,820,000.30 | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | $350,000.10 | 999,381 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.52 | 1,655 | $7,480.60 | 1,442,131 | 2026-02-04 | Filing | |
| $4.61 | 26,918 | $124,091.98 | 1,317,389 | 2026-01-26 | Filing | |
| $4.75 | 89,132 | $423,377.00 | 1,344,307 | 2026-01-23 | Filing | |
| $4.61 | 41,312 | $190,448.32 | 2,908,257 | 2026-01-26 | Filing | |
| $4.75 | 136,789 | $649,747.75 | 2,949,569 | 2026-01-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,643,129 | $102,537,212 | 0% | |
| 2. | 18,078,518 | $99,431,850 | 0.01% | |
| 3. | 16,398,297 | $90,190,634 | 0.9% | |
| 4. | 13,692,739 | $75,310,065 | 0.01% | |
| 5. | 13,528,366 | $74,406,012 | 0% |
News See All
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA)
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy stocks to invest in under $5. Needham maintained a bullish outlook on Taysha Gene Therapies, Inc.
10 Best Strong Buy Stocks to Invest In Under $5
On January 28, JoAnne Feeney, Advisors Capital Management partner and portfolio manager, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends. She was of the view that there is...
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best penny stocks to buy for 2026. On January 6, the company confirmed that the dosing of the first patient in the REVELA pivotal trial began.
10 Best Penny Stocks to Buy for 2026
A rally in large-cap growth stocks was the catalyst behind US equities powering to record highs in 2025.
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program
As of December 17, 2025, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is maintaining levels near its 52-week high, following peaks at $5.95 on December 12 and 13.
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now?
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now.
11 Must-Buy Penny Stocks to Buy Now
Markets have continued to rally, with the S&P 500 already up by about 15% for the year.
Hedge Fund Resource Center